Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICE: Gamunex in CIDP
NCT00220740Phase 3Completed
- Sponsor
- Grifols
- Start
- Apr 2004
- Primary completion
- Jun 2006
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in chronic inflammatory demyelinating polyneuropathy (CIDP) comparing Gamunex with Placebo (2 arms). Primary endpoint: Responder Rate (INCAT Score Improvement) at 6 months. Started Apr 2004; status: completed.
02
Drugs
intravenous human immunoglobulin
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NCT00220740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00220740.